Alamar Biosciences (NASDAQ:ALMR) Stock: Insider Corporate Gp Vi Ltd. Qiming Sells 43,930 Shares

Posted by George Bondi on Nov 5th, 2026

Alamar Biosciences, Inc. (NASDAQ:ALMR – Get Free Report) major shareholder Corporate Gp Vi Ltd. Qiming sold 43,930 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $29.84, for a total value of $1,310,871.20. Following the completion of the sale, the insider owned 160,913 shares of the company’s stock, valued at $4,801,643.92. The trade was a 21.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Corporate Gp Vi Ltd. Qiming also recently made the following trade(s):

On Friday, October 30th, Corporate Gp Vi Ltd. Qiming sold 143,706 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.38, for a total transaction of $4,365,788.28.
On Wednesday, October 28th, Corporate Gp Vi Ltd. Qiming sold 100,837 shares of Alamar Biosciences stock. The shares were sold at an average price of $32.77, for a total value of $3,304,428.49.
On Tuesday, October 27th, Corporate Gp Vi Ltd. Qiming sold 84,894 shares of Alamar Biosciences stock. The stock was sold at an average price of $31.39, for a total value of $2,664,822.66.
On Monday, October 26th, Corporate Gp Vi Ltd. Qiming sold 132,524 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.52, for a total value of $4,044,632.48.
On Friday, October 23rd, Corporate Gp Vi Ltd. Qiming sold 147,934 shares of Alamar Biosciences stock. The stock was sold at an average price of $30.59, for a total value of $4,525,301.06.
On Thursday, October 22nd, Corporate Gp Vi Ltd. Qiming sold 133,811 shares of Alamar Biosciences stock. The stock was sold at an average price of $29.33, for a total value of $3,924,676.63.
On Wednesday, October 21st, Corporate Gp Vi Ltd. Qiming sold 208,815 shares of Alamar Biosciences stock. The shares were sold at an average price of $30.31, for a total value of $6,329,182.65.
On Tuesday, October 20th, Corporate Gp Vi Ltd. Qiming sold 142,004 shares of Alamar Biosciences stock. The shares were sold at an average price of $27.89, for a total value of $3,960,491.56.
On Monday, October 19th, Corporate Gp Vi Ltd. Qiming sold 75,508 shares of Alamar Biosciences stock. The shares were sold at an average price of $26.34, for a total value of $1,988,880.72.
On Friday, October 16th, Corporate Gp Vi Ltd. Qiming sold 136 shares of Alamar Biosciences stock. The stock was sold at an average price of $27.02, for a total transaction of $3,674.72.

Alamar Biosciences Stock Performance

Shares of Alamar Biosciences stock opened at $27.39 on Thursday. The company has a current ratio of 11.85, a quick ratio of 10.23 and a debt-to-equity ratio of 0.03. Alamar Biosciences, Inc. has a 52-week low of $18.84 and a 52-week high of $39.61. The business has a 50 day moving average price of $30.38.

Alamar Biosciences (NASDAQ:ALMR – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.03. The firm had revenue of $33.55 million for the quarter. Sell-side analysts anticipate that Alamar Biosciences, Inc. will post -1.22 earnings per share for the current fiscal year.

Alamar Biosciences News Summary

Here are the key news stories impacting Alamar Biosciences this week:

Positive Sentiment: Alamar reported third-quarter revenue of $33.55 million, up 68% year over year, and a loss of $0.19 per share—narrower than analysts’ expected $0.22 loss. It also raised 2026 revenue guidance to $121 million–$123 million. Alamar Q3 results and guidance
Positive Sentiment: TD Cowen raised its price target to $36 from $34 and maintained a Buy rating; BofA Securities lifted its target to $35 from $31. Higher targets signal continued analyst confidence in the shares. BofA Securities price target update
Positive Sentiment: Alamar and GSK will use Alamar’s NULISA platform in a large-scale proteomics study spanning several disease areas. The collaboration could raise the platform’s profile, although no financial terms were announced. GSK collaboration announcement
Negative Sentiment: Major shareholder Corporate Gp Vi Ltd. Qiming has been selling shares, including 43,930 shares on November 2 and 143,706 on October 30. The repeated sales may add pressure to the stock, though the filings do not give a reason for the transactions. SEC filing on shareholder sales

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ALMR. Weiss Ratings cut shares of Alamar Biosciences from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, October 23rd. TD Cowen upped their price objective on shares of Alamar Biosciences from $34.00 to $36.00 and gave the company a “buy” rating in a research note on Wednesday. Stifel Nicolaus increased their target price on shares of Alamar Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. raised their target price on Alamar Biosciences from $32.00 to $35.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 11th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Alamar Biosciences currently has an average rating of “Hold” and a consensus price target of $33.00.

View Our Latest Analysis on ALMR

Hedge Funds Weigh In On Alamar Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the stock. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Alamar Biosciences by 18.5% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 66,913 shares of the company’s stock valued at $2,280,000 after buying an additional 10,461 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in Alamar Biosciences in the third quarter worth about $196,000. State Street Corp purchased a new stake in Alamar Biosciences in the second quarter worth about $3,930,000. Squarepoint Ops LLC purchased a new stake in Alamar Biosciences in the second quarter worth about $283,000. Finally, Braidwell LP bought a new stake in Alamar Biosciences during the 2nd quarter valued at approximately $29,365,000.

Alamar Biosciences Company Profile

(Get Free Report)

Alamar Biosciences, Inc (NASDAQ: ALMR) is a life sciences company focused on advancing proteomics and enabling earlier detection, diagnosis and monitoring of disease. The company develops technologies designed to measure very low levels of proteins in biological samples, supporting research in areas such as oncology, neurology, immunology and other complex diseases.

Its primary technology is the NULISA platform, a highly sensitive, multiplexed immunoassay system that combines affinity-based protein detection with digital counting.

Insider Buying and Selling by Quarter for Alamar Biosciences (NASDAQ:ALMR)

Receive News & Ratings for Alamar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alamar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.